News & Events
“We are proud of our achievements and want to share our successes. You can find the latest information on our projects, publications and events here.”
Leading ALS authority Merit Cudkowicz joins TikoMed’s newly formed Scientific Advisory Board
22 september 2023
Viken – September 19, 2023 – Today, Swedish biopharmaceutical company TikoMed AB announced the formation of its Scientific Advisory Board…
TikoMed’s ILB® inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
21 september 2022
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies Viken, Sweden…
TikoMed’s drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action
8 september 2022
Viken, Sweden – 7th September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining…
New peer-reviewed research shows TikoMed’s ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target neuroinflammation-driven diseases including Amyotrophic Lateral Sclerosis
31 augusti 2022
Viken, Sweden – 31st August 2022 – TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body’s…
TikoMed’s ILB® activates the body’s natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a rat model of severe traumatic brain injury
3 augusti 2022
Viken – 3rd August 2022 – A new study with TikoMed’s lead drug candidate, ILB®, addressing underlying causes of neurodegeneration…
TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE
25 maj 2022
Viken – 25th May, 2022 – A new study with TikoMed’s platform lead clinical drug candidate ILB®, provides positive safety…
TIKOMED’S ILB® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in patients with ALS in data published by the Journal of Personalized Medicine
16 augusti 2021
Viken – 16th August 2021 – New study results for Tikomed’s platform lead drug candidate ILB® in the treatment of…
TIKOMED’S ILB® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine
26 januari 2021
Viken – 7 January 2021 – A new study on TIKOMED’s lead drug candidate, ILB®, was published in npj Regenerative Medicine today….
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
14 september 2020
Viken – 14th September 2020 – A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying…